热休克蛋白90抑制剂：从格尔德霉素到当今药物的历程

Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.

作者信息

Chiosis Gabriela, Caldas Lopes Eloisi, Solit David

机构信息

Memorial Sloan-Kettering Cancer Center, Department of Medicine and Program in Molecular Pharmacology and Chemistry, 1275 York Avenue, New York, NY 10021, USA.

出版信息

Curr Opin Investig Drugs. 2006 Jun;7(6):534-41.

PMID:16784024

Abstract

Heat shock protein (Hsp)90 is a chaperone with essential roles in maintaining transformation and in elevating the survival and growth potential of cancer cells. The recognition of Hsp90 as an important target in cancer therapy has prompted the identification, development and clinical translation of a large array of Hsp90 inhibitors. This review discusses the modalities that may interfere with this chaperone's function and describes the status of existing and emerging Hsp90 inhibitor classes.

摘要

热休克蛋白（Hsp）90是一种伴侣蛋白，在维持癌细胞的转化以及提高其生存和生长潜力方面发挥着重要作用。Hsp90被认为是癌症治疗的重要靶点，这促使人们鉴定、开发并将大量Hsp90抑制剂应用于临床。本文综述了可能干扰这种伴侣蛋白功能的作用方式，并描述了现有及新出现的Hsp90抑制剂类别的研究现状。